Renal Cell Carcinoma Excellence Forum

Renal Cell Carcinoma

Excellence Forum

Laurence Albiges, MD, PhD, Gustave Roussy

Videos

Addition of Cabozantinib to Nivolumab-Ipilimumab for Advanced Renal Cell Carcinoma in the First-Line Setting

03/13/2025

Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.

Laurence Albiges, MD, PhD,...

03/13/2025

Oncology

Conference Coverage

Nivolumab Plus Axitinib for Previously-Treated Patients With Advanced Renal Cell Carcinoma

02/27/2025

Matthew Zibelman , MD;

Matthew Zibelman, MD, discusses results from a phase 1/2 study which evaluated nivolumab plus axitinib as a treatment option for previously-treated patients with advanced renal cell carcinoma.

Matthew Zibelman, MD, discusses...

02/27/2025

Oncology

Conference Coverage

Impact of Ipilimumab-Nivolumab Dosage for Patients With Metastatic Renal Cell Carcinoma

02/27/2025

Sahil Doshi , MD;

Sahil Doshi, MD, discusses retrospective study results which demonstrated that patients with metastatic renal cell carcinoma who had less than the recommended 4 doses of ipilimumab plus nivolumab had similar overall survival outcomes as those...

Sahil Doshi, MD, discusses...

02/27/2025

Oncology

Conference Coverage

Durvalumab Plus Savolitinib for Patients With MET-Driven Advanced Papillary Renal Cancer

02/26/2025

Francesca Jackson-Spence , MBChB;

Francesca Jackson-Spence, MBChB, discusses final efficacy and ctDNA data from the CALYPSO trial which demonstrated that durvalumab plus savolitinib prolonged efficacy among patients with MET-driven advanced papillary renal cancer.

Francesca Jackson-Spence, MBChB,...

02/26/2025

Oncology

Conference Coverage

Lenvatinib Plus Belzutifan Shows Promise for Advanced Clear Cell Renal Cell Carcinoma

02/25/2025

Katy Beckermann , MD;

Katy Beckermann, MD, discusses results from the KEYMAKER-U03 Substudy 03B, evaluating pembrolizumab in combination with targeted therapy agents for patients with advanced clear cell renal cell carcinoma.

Katy Beckermann, MD, discusses...

02/25/2025

Oncology

Videos

Nivolumab Plus Ipilimumab Improves Overall Survival Over Standard of Care Therapy in Advanced Non-Clear Cell Renal Cancer

09/14/2024

Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.

Lothar Bergmann, MD, discusses...

09/14/2024

Oncology

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Thomas Powles , MBBS, MD;

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Conference Coverage

Subcutaneous Nivolumab Noninferior to Intravenous Administration Among Patients With Clear Cell Renal Cell Carcinoma

01/27/2024

Saby George , MD;

Saby George shares insights from the CheckMate 67T evaluating the subcutaneous administration of nivolumab for patients with clear cell renal cell carcinoma, compared with the intravenous administration.

Saby George shares insights from...

01/27/2024

Oncology

Recent News

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada ;

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada ;

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada ;

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland ;

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey ;

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey ;

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley ;

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey ;

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland ;

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland ;

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology